Skip to main content
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC — Investor Relations & Filings

Ticker · ADAP ISIN · US00653A1079 LEI · 549300UUNWK8TRT5EW12 US Manufacturing
Open in API
Filings indexed 807 across all filing types
Latest filing 2020-05-29 Declaration of Voting R…
Country GB United Kingdom
Listing US ADAP

About Adaptimmune Therapeutics PLC

https://www.adaptimmune.com/

Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company specializing in the development of novel T-cell receptor (TCR) T-cell therapies for cancer. The company utilizes a proprietary platform to engineer a patient's own T-cells to recognize and fight solid tumors. Its first FDA-approved therapy, Tecelra (afami-cel), is a treatment for advanced synovial sarcoma. Adaptimmune is advancing a robust pipeline of cell therapies, including preclinical programs targeting PRAME and CD70, as well as an allogeneic platform. The company's mission is to deliver transformative, potentially single-infusion treatments to reshape cancer care for patients with difficult-to-treat solid tumors.

Recent filings

Filing Released Lang Actions
FORM-8K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated May 29, 2020, reporting the submission of matters to a vote of security holders at the company's Annual General Meeting (AGM). It details the voting results on various resolutions including director re-elections, auditor appointments, and share allotment authorizations. The content focuses on the official results of shareholder votes at the AGM, which aligns with the category for Declaration of Voting Results & Voting Rights Announcements (DVA). The document is not the AGM presentation itself, nor is it a full annual report or proxy statement. It is a formal announcement of voting outcomes from the AGM, fitting the DVA category with high confidence.
2020-05-29 English
FORM 10-Q/A
Interim / Quarterly Report Q1 2020
2020-05-28 English
10-Q
Interim / Quarterly Report Q1 2020
2020-05-14 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 14, 2020, by Adaptimmune Therapeutics plc. It announces the issuance of a press release containing financial results for the first quarter ended March 31, 2020. The document itself does not contain detailed financial statements or substantive financial data but references an attached press release (Exhibit 99.1) that contains the financial results. The document is relatively short (3,677 characters) and serves as a notification of the earnings release rather than the earnings release itself. According to the 'Menu vs Meal' rule, this is an announcement of a report (press release) rather than the report itself. Therefore, the appropriate classification is Earnings Release (ER), as the document announces quarterly financial results.
2020-05-14 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or disclosures by a company. The text references a press release about a presentation of data at a conference, specifically a Regulation FD Disclosure. It does not contain financial statements or detailed financial data, nor is it an annual or quarterly report. The document is relatively short (3791 characters) and primarily announces the issuance of a press release and presentation. Therefore, it is not a full financial report but a regulatory filing announcing an event or disclosure. According to the rules, such filings that do not fit other categories and are announcements fall under Regulatory Filings (RNS).
2020-05-12 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the U.S. Securities and Exchange Commission (SEC) by Adaptimmune Therapeutics plc, dated April 29, 2020. It discusses the company's reliance on an SEC order to delay the filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2020, due to COVID-19 related disruptions. The document includes a business update related to COVID-19 impacts, a notice of an upcoming earnings release and webcast scheduled for May 14, 2020, and a supplemental risk factor related to the pandemic. The document is a current report (Form 8-K) providing updates and disclosures about events and other information, including the delay of the quarterly report and business impacts, but it does not contain the actual quarterly financial statements or detailed financial data itself. Therefore, it is not an Interim/Quarterly Report (IR) or Earnings Release (ER), but rather a regulatory filing providing material event disclosure. Given the nature and content, the appropriate classification is Regulatory Filings (RNS). The document length (15,000 characters) and detailed content support this classification with high confidence.
2020-04-29 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.